Can Fite BioPharma Ltd (CANF) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

RAMAT GAN, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]